|Type||Public / Private|
|Industry||Pharmaceuticals, Vaccines and Consumer Healthcare|
|Slogan||Do more Feel Better live longer|
|Headquarters||980 Great West Road Brentford Middlesex TW8 9GS United Kingdom|
|Key people|| Emma Walmsley (CEO) |
Roger Connor President, Global Manufacturing & Supply
Luc Debruyne President, Global Vaccines
GlaxoSmithKline started operations on 1 January 2001 following the merger of GlaxoWellcome plc and SmithKline Beecham plc.
Top 5 Recent Tweets
|March 15, 2021||ABNewswire||Covid-19 Vaccine Market to Eyewitness Massive Growth by 2026 | GlaxoSmithKine, Pfizer, JohnsonJohnson… https://t.co/Fa3CRT3wqS|
|March 13, 2021||sikkim_journal||Covid-19 Vaccine Market to Eyewitness Massive Growth by 2026 | GlaxoSmithKine, Pfizer, JohnsonJohnson https://t.co/V2PJx060QY|
|March 13, 2021||PressRelease_cc||Covid-19 Vaccine Market to Eyewitness Massive Growth by 2026 | GlaxoSmithKine, Pfizer, JohnsonJohnson https://t.co/ZSlVLPxDA9|
Top 5 Recent News Headlines
GlaxoSmithKline plc GSK announced that the FDA has approved the label expansion of eosinophilic asthma drug, Nucala, to include treatment of eosinophilic granulomatosis with polyangiitis ("EGPA"). With this approval, Nucala becomes the first targeted treatment for EGPA, which was previously known as Churg-Strauss syndrome.
EGPA is a rare autoimmune disease, which causes inflammation in small and medium-sized blood vessels. It can cause damage to lungs, sinuses, skin, heart, gastrointestinal tract, nerves and other organs.
Nucala is presently approved for treating severe eosinophilic asthma.